These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 31625769)

  • 21. Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study.
    Bonifati C; De Felice C; Lora V; Morrone A; Graceffa D
    J Dermatolog Treat; 2020 Nov; 31(7):687-691. PubMed ID: 30985223
    [No Abstract]   [Full Text] [Related]  

  • 22. The Experience with Biosimilars of Infliximab in Rheumatic Diseases.
    Azevedo VF; Kos IA; Ariello L
    Curr Pharm Des; 2017; 23(44):6752-6758. PubMed ID: 29189135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis.
    Ditto MC; Parisi S; Priora M; Sanna S; Peroni CL; Laganà A; D'Avolio A; Fusaro E
    Sci Rep; 2020 Sep; 10(1):16178. PubMed ID: 32999362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor necrosis factor inhibitors in psoriatic arthritis.
    Mantravadi S; Ogdie A; Kraft WK
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):899-910. PubMed ID: 28490202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection.
    Atteno M; Costa L; Matarese A; Caso F; Del Puente A; Cantarini L; Bocchino ML; Sanduzzi A; Scarpa R
    Clin Rheumatol; 2014 Apr; 33(4):543-7. PubMed ID: 24554385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.
    Buurman DJ; Blokzijl T; Festen EAM; Pham BT; Faber KN; Brouwer E; Dijkstra G
    PLoS One; 2018; 13(12):e0208922. PubMed ID: 30533022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis.
    McClean AR; Cheng L; Bansback N; Clement F; Tadrous M; Harrison M; Law MR
    Arthritis Care Res (Hoboken); 2023 Sep; 75(9):2011-2021. PubMed ID: 36752358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitals.
    Jarrion Q; Azzouz B; Robinson J; Jolly D; Vallet C; Trenque T
    Therapie; 2022; 77(4):467-475. PubMed ID: 35027238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
    Bruni C; Bitti R; Nacci F; Cometi L; Tofani L; Bartoli F; Fiori G; Matucci-Cerinic M
    Clin Rheumatol; 2021 Jan; 40(1):85-91. PubMed ID: 32514676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis.
    Ruda RC; Kelly KA; Feldman SR
    J Dermatolog Treat; 2023 Dec; 34(1):2140569. PubMed ID: 36305624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-tumor necrosis factor α: originators
    Gioia C; Picchianti Diamanti A; Perricone R; Chimenti MS; Afeltra A; Navarini L; Migliore A; Massafra U; Bruzzese V; Scolieri P; Meschini C; Paroli M; Caccavale R; Scapato P; Scrivo R; Conti F; Laganà B; Di Franco M
    Reumatismo; 2023 Dec; 75(4):. PubMed ID: 38115772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P; Fiorino G; Danese S
    Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
    Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F
    Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study.
    Aaltonen K; Heinonen A; Joensuu J; Parmanne P; Karjalainen A; Varjolahti-Lehtinen T; Uutela T; Puurtinen-Vilkki M; Arstila L; Blom M; Sokka T; Nordström D
    Semin Arthritis Rheum; 2017 Jun; 46(6):732-739. PubMed ID: 28010883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
    Argollo M; Fiorino G; Gilardi D; Furfaro F; Roda G; Loy L; Allocca M; Peyrin-Biroulet L; Danese S
    Curr Pharm Des; 2019; 25(1):7-12. PubMed ID: 30864505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical experience with the etanercept biosimilar SB4 in psoriatic patients.
    Pescitelli L; Lazzeri L; Di Cesare A; Tripo L; Ricceri F; Prignano F
    Int J Clin Pharm; 2019 Feb; 41(1):9-12. PubMed ID: 30610544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.
    Nabi H; Hendricks O; Jensen DV; Loft AG; Pedersen JK; Just SA; Danebod K; Munk HL; Kristensen S; Manilo N; Colic A; Linauskas A; Thygesen PH; Christensen LB; Kalisz MH; Lomborg N; Chrysidis S; Raun JL; Andersen M; Mehnert F; Krogh NS; Hetland ML; Glintborg B
    RMD Open; 2022 Nov; 8(2):. PubMed ID: 36418087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System.
    Jourdain H; Hoisnard L; Sbidian E; Zureik M
    RMD Open; 2024 Mar; 10(1):. PubMed ID: 38453213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.